



**HAL**  
open science

## No Immune Risk Profile among individuals who reach 100 years of age: Findings from the Swedish NONA Immune Longitudinal Study

Jan Strindhall, Bengt-Olof Nilsson, Sture Löfgren, Jan Ernerudh, Graham Pawelec, Boo Johansson, Anders Wikby

► **To cite this version:**

Jan Strindhall, Bengt-Olof Nilsson, Sture Löfgren, Jan Ernerudh, Graham Pawelec, et al.. No Immune Risk Profile among individuals who reach 100 years of age: Findings from the Swedish NONA Immune Longitudinal Study. *Experimental Gerontology*, 2007, 42 (8), pp.753. 10.1016/j.exger.2007.05.001 . hal-00499016

**HAL Id: hal-00499016**

**<https://hal.science/hal-00499016>**

Submitted on 9 Jul 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

No Immune Risk Profile among individuals who reach 100 years of age: Findings from the Swedish NONA Immune Longitudinal Study

Jan Strindhall, Bengt-Olof Nilsson, Sture Löfgren, Jan Ernerudh, Graham Pawelec, Boo Johansson, Anders Wikby


PII: S0531-5565(07)00094-0  
DOI: [10.1016/j.exger.2007.05.001](https://doi.org/10.1016/j.exger.2007.05.001)  
Reference: EXG 8341

To appear in: *Experimental Gerontology*

Received Date: 31 January 2007  
Revised Date: 27 April 2007  
Accepted Date: 4 May 2007

Please cite this article as: Strindhall, J., Nilsson, B-O., Löfgren, S., Ernerudh, J., Pawelec, G., Johansson, B., Wikby, A., No Immune Risk Profile among individuals who reach 100 years of age: Findings from the Swedish NONA Immune Longitudinal Study, *Experimental Gerontology* (2007), doi: [10.1016/j.exger.2007.05.001](https://doi.org/10.1016/j.exger.2007.05.001)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**No Immune Risk Profile among individuals who reach 100 years of age:  
Findings from the Swedish NONA Immune Longitudinal Study**

Jan Strindhall<sup>1</sup>, Bengt-Olof Nilsson<sup>2</sup>, Sture Löfgren<sup>3</sup>, Jan Ernerudh<sup>4</sup>,  
Graham Pawelec<sup>5</sup>, Boo Johansson<sup>6</sup>, Anders Wikby<sup>1\*</sup>

1. Department of Natural Science and Biomedicine, School of Health Sciences, Jönköping University, Box 1026, 551 11 Jönköping, Sweden
2. Department of Infectious Diseases, Ryhov Hospital, 551 85 Jönköping, Sweden
3. Department of Microbiology, Ryhov Hospital, Jönköping, Sweden
4. Division of Clinical Immunology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden
5. University of Tübingen Medical School, Center for Medical Research, ZMF, Waldhörlestr. 22, D-72072 Tübingen, Germany
6. Institute of Gerontology, School of Health Sciences, Jönköping University, Box 1026, 551 11 Jönköping, Sweden and Department of Psychology, Göteborg University, Box 500, 405 30 Göteborg, Sweden

Key words: Immune Risk, T-cells, Centenarians, Survival

\* Corresponding author: Tel.: + 46-381-35101; fax: + 46-381-35341.

*E-mail address:* anders.wikby@hhj.hj.se

**Abstract**

In the present NONA immune longitudinal study, we investigate the previously identified Immune Risk Profile (IRP), defined by an inverted CD4/CD8 ratio and associated with persistent cytomegalovirus infection and increased numbers of CD8+CD28- cells, relative 6-year survival and age in NONA individuals. These subjects have now reached age 92, 96, and for the first time in this study, 100 years at follow-up. A 55 year old middle-aged group was used for comparison. Immunological monitoring included the analysis of numbers of lymphocytes and neutrophils, the T-cell subsets CD3+CD4+, CD3+CD8+, CD8+CD28+, CD8+CD28-, and the CD4/CD8 ratio. Longitudinal data were analysed by multivariate analyses of variance (MANOVA) from four measurement occasions at 2-year inter-intervals. Oneway ANOVA was used for cross-sectional comparisons at baseline and the 6-year follow-up. The results confirmed the importance of the IRP as a major predictor of mortality in this population of very old. Moreover, the results suggested that survival to the age of 100 years is associated with selection of individuals with an “inverted” IRP that was stable across time, i.e. maintenance of a high CD4/CD8 ratio and low numbers of CD8+CD28-cells. The results underlines the importance of a longitudinal study design in dissecting immune parameters predictive of survival and show for the first time that centenarian status is associated with avoidance of the IRP over at least the previous 6 years and probably throughout life.

## 1. Introduction

Throughout the 20<sup>th</sup> century, a remarkable increase in mean lifespan and possibly also maximum longevity has taken place in humans. A substantial number of centenarians reached the age of 110 already in the 1960s in larger European countries (Jeune, 2002). Centenarians today have experienced major improvements in their overall health and living conditions, for example a decline in mortality due to cardiovascular diseases at younger ages. The increased numbers of centenarians in recent decades is mainly due to a dramatic decline in the mortality rate among those above 80-years of age (Jeune, 2002). The rate of mortality due to cardiovascular disease or cancer increases with age from middle age up to about 80 year old and levels off thereafter, whereas the mortality due to infectious disease continue to accelerate also in very late life (reviewed in Pawelec et al., 2006). The ageing human body is less able to cope with infectious disease probably due to changes in innate and especially adaptive immunity (Delarosa et al., 2006; Solana et al. 2006). The immune system may thus be considered decisive for successful ageing and longevity in humans. The present NONA immune longitudinal study examines age-related changes relative to survival across a 6-year follow-up period among very old individuals.

There is considerable evidence of age-associated changes in immune capabilities resulting in increased morbidity and mortality due to altered function of the adaptive immune system (Wayne et al., 1990). An Immune Risk Profile (IRP), consisting of high CD8, low CD4 numbers, and poor proliferative response to Con A, was initially identified in the Swedish OCTO Immune Longitudinal Study using a cluster analysis approach (Ferguson et al., 1995). Subsequent work indicated that the IRP could be defined using only the inverted CD4/CD8 ratio, since this sole marker is significantly associated with the IRP (Wikby et al., 1998). More recent investigations have extended these results to show that cytomegalovirus (CMV) infection has a major impact on the IRP and may in fact be the major driving force behind the accumulation of many of the CD8+CD28- effector cell expansions observed (Olsson et al., 2000; Reker Hadrup et al. 2006).

Findings in the Swedish OCTO Immune Longitudinal Study provided the basis for the subsequent ongoing NONA Immune Longitudinal Study of very old individuals investigated independently of health status at baseline ages 86, 90, and 94 years old. Follow-ups were performed at three occasions after 2, 4, and 6 years (Wikby et al, 2002). Importantly, it was found that the IRP was largely independent of disease status in this sample in which three quarters of the individuals met criteria for compromised health and only 9% conformed to the SENIEUR inclusion criteria for excellent health at baseline (Nilsson et al., 2002).

The aim of the present data analysis at the 6-year follow-up of the NONA immune longitudinal follow-up was to examine the relative importance of the IRP relative to mortality and age. Considering

that the oldest cohort had now become centenarians, commonly taken as a paradigm for “successfully ageing”, we addressed the question of whether the “successfully aged” are exceptional in their avoidance of the IRP and show here that the centenarians never entered this at-risk category.

## **2. Materials and Methods**

### *2.1 Subjects*

The NONA immune sample was recruited from participants in the NONA Longitudinal Study, in which a population-based sample of oldest-old individuals are investigated with a broad-based battery of tests for health and biobehavioral functioning. The NONA sample was drawn in the municipality of Jönköping, located in South-Central Sweden.

The sampling frame of the NONA study was based on available census information in September 1999 by means of which a non-proportional sampling procedure was employed including all individuals permanently residing in the municipality. The goal was to have an equal number of individuals aged 86, 90, and 94, and to compare those with a healthy group of individuals (n=13) with the mean age of 49 years. As the number of available subjects in the oldest birth cohort was limited, a few subjects were also included into this from the birth cohorts of 1904 and 1906. No exclusion criteria of compromised health were employed in the NONA immune study.

Blood was drawn at baseline from 138 individuals (42 belonged to the oldest birth cohort, 47 were 90 years and 49 were 86 years old). After 6 years, 99 (72%) were deceased. Another 8 declined to participate at this forth wave, giving a total number of 31 participants for the present longitudinal analyses through the four time points T1 (1999), T2 (2001), T3 (2003) and T4 (2005) (table 1). About 60 percent resided in ordinary housing at the 6-year follow-up (often with support from the home help system), while 40% were in sheltered housing or in institutions.

Subjects were examined in their place of residence by trained Registered Nurses (RNs) having extensive work experience with the elderly. The blood samples were drawn in the morning between 09.00 and 10.00. The health and biobehavioral functioning battery took about 3 hours to administer, including breaks, for individuals who were able to participate in all parts. The battery encompassed an interview, biomedical and behavioural assessments and ratings. The health interview focused on diagnosed illnesses, current symptoms and medications, using a combination of self-reports and medical records. An informant interview was performed in all cases where the individual was unable to participate in full due to compromised health and cognitive ability. The study was approved by the local ethics committee.

## 2.2 Preparation of plasma and peripheral blood mononuclear cells

Plasma was prepared from 40 ml fresh EDTA blood by centrifugation at 2500 rpm for 10 minutes and was removed and stored at  $-80^{\circ}\text{C}$ . Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation on Lymphoprep<sup>®</sup> (Nycomed Diagnostika, Oslo, Norway) and washed three times in Dulbecco's PBS (D-PBS). The cells were resuspended in complete medium consisting of RPMI 1640 (Invitrogen Life Technologies, Stockholm, Sweden), supplemented with 10% inactivated ( $56^{\circ}\text{C}$ , 30 min) fetal calf serum (In Vitro Sweden AB, Stockholm), 2 mM L-glutamine, 50 U/ml penicillin and 50  $\mu\text{g/ml}$  streptomycin (Gibco, Stockholm, Sweden). Isolated PBMC counts, differential counts, white blood cell counts, complete blood cell counts and examination of the whole blood were performed as previously described (Wikby et al., 1994).

## 2.4 Flow cytometric analysis

Monoclonal antibodies (Mabs), including appropriate isotype controls, were purchased from BD Biosciences (Stockholm, Sweden). The data were acquired using a FACScan (BD Biosciences) and analysed using CELLQuest software (BD Biosciences). The staining protocol for three-colour staining included the CD3Per-CP/CD4FITC/CD8PE and CD3Per-CP/CD8FITC/CD28PE combinations in tubes 4 and 5, respectively. In tube 1 Control IgG1FITC/IgG1PE/IgG1Per-CP was used to create an analysis gate to include lymphocytes in FSC vs SSC and to set the fluorescence quadrant markers on the FL1 versus FL2 to detect the presence of any nonantigen-specific antibody binding (nonspecific staining). In tube 2 CD3 FITC/CD4PE/CD8Per-CP was used to create a gate set on the CD3 positive lymphocyte fraction and to adjust compensation on FL1 versus FL2. Quality control was performed using daily CaliBRITE beads and FACSCComp software (BD Biosciences) for setting the photomultiplier tube (PMT) voltages, the fluorescence compensation and checking instrument sensitivity prior to use. Internal quality control was performed to check consistency for CD markers included in more than one tube and resulted in a coefficient of variation of 5-7%.

## 2.5 The CD4/CD8 ratio

CD4/CD8 ratio (numbers of CD4 and CD8 cells) less than 1.00 was used to identify IRP individuals. Using CD4 and CD8 percentages resulted in an identical CD4/CD8 ratio categorisation.

## 2.6 Health parameters

The overall health status of the NONA immune subjects ( $n=138$ ) indicated that only 13 individuals (9.4%) were rated as "healthy" at baseline, according to the European SENIEUR protocol criteria often used in studies of aging and immunology (Nilsson et al., 2003). Thirty-eight (27.5%) met the criteria for not residing in an institution, not being demented or using medication known to effect the immune system employed in the OCTO Immune Study (Wikby et al., 1994) and here termed

“moderately healthy”. The remaining sample (63.0%) comprised “frail” individuals, not meeting the above health criteria (Nilsson et al., 2003).

### 2.7. Cytomegalovirus (CMV) serology

Immunoassay (MEIA, ABBOT Scandinavia AB, Sweden) was used to detect anti-CMV immunoglobulin G antibodies. The procedure followed the manufacturer's instruction. Antibody titers of >40 were considered to be positive.

### 2.8. Data analysis

Statistical analyses were conducted using SPSS11. Analysis of variance (ANOVAs) with Tukey's post-hoc tests and Student t-tests were employed for comparisons of independent groups. Correlation analysis was performed using the Pearson correlation coefficient. Longitudinal analysis of numbers of neutrophils, lymphocytes, and subsets of T-cells was done by means of multivariate analyses of variance (MANOVA), repeated measures design.

## **3. Results**

### Cross-sectional data at baseline and 6-year follow-up.

#### *Neutrophils, lymphocytes and T-cell subsets by age groups*

The numbers of neutrophils, lymphocytes, T-cells and subsets and the CD4/CD8 ratio were compared between the age groups 55, 92, 96, and 100 years old by one-way ANOVA. At baseline there were significant overall between group differences for the numbers of CD8+CD28- ( $p<0.01$ ) and CD8+CD28+ ( $p<0.05$ ) with higher numbers of CD8+CD28- and lower numbers of CD8+CD28+ T-cells in the very old compared with the middle-aged. There were no significant differences between the age groups in very old individuals. Neither were significant differences between the various age groups found for the numbers of neutrophils, lymphocytes, CD3+, CD3+CD4+, CD3+CD8+ cells or the CD4/CD8 ratio (data not shown).

The numbers of neutrophils, lymphocytes, T-cells and subsets and the CD4/CD8 ratio were also compared across age groups at the 6-year follow-up (figures 1 and 2). One-way ANOVA showed significant overall between group differences for the numbers of neutrophils ( $p<0.05$ ), CD3+ ( $p<0.01$ ), CD3+CD4+ ( $p<0.01$ ), CD3+CD8+ ( $p<0.05$ ), CD8+CD28+ ( $p<0.001$ ), CD8+CD28- ( $p<0.05$ ) and for the CD4/CD8 ratio ( $p<0.01$ ). Tukey post-hoc tests showed significantly ( $p<0.05$ ) higher numbers of neutrophils in the group of 100 years, as compared with the 55 year old group (figure 1a). Significantly lower numbers of CD3+ and CD3+CD4+ T-cells was found for the 96 year old group, compared with the group of middle-aged (figure 1b). The post-hoc test also showed significant



differences among all elderly groups and the 55 year old group for CD8+CD28+ with lower numbers of cells among the very old, as compared with the middle-aged (figure 2a). Greater numbers of CD8+CD28- cells were found for the 92 year group as compared with the 55, 96, and 100 year age groups (figure 2a), and the post-hoc test indicated that the mean differences between the 92 and the 100 year old groups approached significance ( $p=0.07$ ). Higher CD4/CD8 ratio were found for the 96 and 100 year old groups, as compared with the 92 and 55 groups. Post-hoc significances ( $p<0.05$ ) for the mean differences was obtained comparing the 100 year old group with the 92 year olds and the middle-aged.

A plot of the number of CD8+CD28- T-cells versus the natural logarithm of the CD4/CD8 ratio at 6-year follow-up is shown in Figure 3. The figure demonstrates a close negative association between the parameters. It is also seen that a majority of individuals in the youngest 92 year old group indicated lower CD4/CD8 ratios associated with elevated numbers of CD3+CD8+CD28- cells while the majority of individuals in the 96 and 100 year old groups showed higher ratios and lower numbers of CD3+CD8+CD28- cells.

#### *Prevalence of CMV carrier status and relationship with T-cell subsets and CD4/CD8 ratio in the old*

One hundred and twenty individuals out of 138 were CMV-IgG positive at baseline. This corresponds to an overall CMV prevalence of 87%, which is significantly higher compared with the prevalence rate of 55% (10 out of 18) found in the middle-aged. At 6-year follow-up the CMV-IgG prevalence was 80.6% (25 out of 31) in the very old compared to a prevalence of 61.1 (11 out of 18) among middle-aged ( $p=0.12$ ). There were no significant differences in the CMV-IgG prevalence among the older age groups, although the centenarian group indicated a lower prevalence of 71.4% (5 out of 7) as compared to the prevalence of 83.3% (20 out of 24) among the 92-96 years olds. There was also a relationship between the prevalence of the CMV carrier and the number of CD8+CD28- cells (59 and 225 cells/ $\mu$ l in CMV- (n=6) and CMV+ individuals (n=25) respectively,  $p<0.05$ ) and the CD4/CD8 ratio (2.6 and 4.3 in CMV- (n=6) and CMV+ individuals (n=25) respectively,  $p<0.05$ ) at 6-year follow-up, which was similar to the results found at baseline (no data shown).

#### **Longitudinal data**

##### *Neutrophils and lymphocytes*

A MANOVA indicated that the numbers of neutrophils were significantly higher ( $p<0.05$ ) in the groups of very old as compared with the 55 year middle-aged group. The MANOVA also indicated a significant interaction effect between age groups and time, demonstrating a more rapid increase in the levels of neutrophils across time in the very old as compared to the 55 year old middle-aged group ( $p<0.05$ ) (Table 2). The MANOVA showed no significant effects of group, time or group by time for

the number of lymphocytes (Table 2) but there was a tendency for the number of lymphocytes to decrease with time in the 96 and 100 year old groups.

#### *CD3+CD4+, CD3+CD8+ and CD4/CD8 ratio*

As shown in table 3 the MANOVA showed no significant effects of group, time or group by time for the number of CD3+CD4+ and CD3+CD8+ T-cells comparing the 55, 92, 96 and 100 year old age groups, although a tendency for the number of CD3+CD4+ cells to decrease with time in the 96 and 100 year old groups was noticed. For the CD4/CD8 ratio there was a significant ( $p<0.05$ ) effect of age group with the 96 and 100 year groups indicating higher ratio as compared with the 55 and 92 year old groups (Table 3).

#### *CD8+CD28+ and CD8+CD28-*

The MANOVA indicated significant differences between age groups for CD8+CD28+ ( $p<0.001$ ) and CD8+CD28- ( $p<0.05$ ) numbers, with a lower number of CD8+CD28+ cells in the very old age groups as compared with 55 year old middle-aged and a greater number of CD8+CD28- cells for the 92 year old group as compared with the other age groups (Table 4). Noteworthy, there was a tendency for the number of CD8+CD28- cells to increase over time in the 55 and 92 year old groups and for the number of CD8+CD28+ cells to decrease with time in the 96 and 100 year old groups.

#### *Mortality data*

A comparison of the number of neutrophils, lymphocytes, T-cell subsets, CD4/CD8 ratio and relative numbers of very old individuals with a CD4/CD8 ratio less than one using immune data at baseline was made between those who had survived and not survived at 6-year follow-up, see Table 5. A Student's t-test indicated significantly greater numbers of neutrophils and CD8+CD28- cells in non-survivors as compared with survivors. Moreover, the data showed that none of the 22 very old individuals with an inverted CD4/CD8 ratio at baseline had survived at 6-year follow-up ( $p<0.001$ ).

During the six year longitudinal study, 5 very old individuals developed a CD4/CD8 ratio less than one by increases in the number of CD8+ cells and decreases in the number of CD4+ cells. Of these 4 were diseased at 6-year follow-up, leaving only one individual with a CD4/CD8 ratio less than one at 6-year follow-up (data not shown).

#### 4. Discussion

This study used a longitudinal design that permitted an examination of age-related changes in a population based sample of very old Swedish people.

The initial cross-sectional analysis of data at baseline and the 6-year follow-up demonstrated differences between the very old and middle-aged for the CD8+CD28+ and CD8+CD28- T-cell subsets on both occasions, confirming a loss of CD28 expression with increased age and seen previously in our own and other studies (reviewed in Effros et al, 2004). At 6-year follow-up, however, significant differences between age groups not seen at baseline appeared in the CD3+, CD3+CD4+, CD3+CD8+ subsets as well as in the CD4/CD8 ratio, results that can be interpreted as real age-related changes in the very old between baseline and 6-year follow-up. However, longitudinal data revealed no significant changes across the six year period in any of the T-cell subsets. These findings support the interpretation that the observed differences in the 6-year cross-sectional mean values result from selective mortality such that subjects alive at follow-up display an immune profile associated with survival. Consequently, individuals surviving until the age of 100 years do not display any T-cell changes associated with the Immune Risk Profile, i.e. they retain low numbers of CD8+CD28-, CD3+CD8+ and CD3+ cells and high CD4/CD8 ratio (Ferguson et al., 1995), also predominant when these “successfully aged” people were younger (Tables 2 and 3). The interpretation is further supported by the finding that all individuals in the centenarian group showed CD4/CD8 ratios (range 1.8-6.5,  $\ln(\text{CD4/CD8})$  range 0.6-1.9) well separated from the IRP cut-off 1.00, while among ten cases closer to that border (range 0.8-1.6,  $\ln(\text{CD4/CD8})$  range -0.2-0.5), nine (including the one single IRP individual) belonged to the youngest age group (92 years old), and one to the 96 year old group (Figure 1). Finally, the conclusion is supported by the fact that the prevalence of IRP decline from 16% at baseline to 3 % at 6-year follow-up, when individuals in the NONA sample had become 95 years old on average.

Although the longitudinal data did indicate no significant changes over time for lymphocytes, T-cells or T-cell subsets some minor time changes should be mentioned. The data suggest a tendency of a decline in the oldest NONA individuals, 96 and 100 year old at 6-year follow-up, for the number of lymphocytes in the CD3+, CD3+CD4+ and CD8+CD28+ subsets. This result may reflect that the very old sample includes subjects who experience changes at the end of their life span, similarly to results found in the Baltimore Longitudinal Study of Aging. The study demonstrated that the lymphocyte counts began to decrease 3 years prior to death in a majority of the very old individuals examined (Bender et al., 1986). Avoidance of an IRP in the centenarian and 96 year old groups was associated with a major loss of CD8+ T-cells (figure 1b), which to some extent might be associated with the decline in the CD8+CD28+ subset across time as described above. A more important reason for the low CD8+ numbers in individuals reaching 100 years of age, however, seem to be the selective

survival of individuals having the ability to control CMV and avoiding the accumulation of apoptosis resistant CD8+CD28- T-cells. We also found a tendency for the number of CD8+CD28- cells to increase with time in the “younger” 55 and 92 year old groups, which might reflect early change towards the development of an IRP. The association between the number of CD8+CD28- cells and CD4/CD8 ratio, as presented for the very old individuals in figure 1, conform with previous findings (Effros et al., 1994).

We investigated 6-year mortality in very old individuals categorized by having or not having an IRP defined as a CD4/CD8 ratio of less than one. The results showed that all of the 22 individuals that resided in the IRP category at baseline in fact were deceased at the 6-year follow-up. This confirms previous findings from the OCTO Immune Longitudinal Study that the IRP constitute a major predictor of survival (Wikby et al., 2006). The conclusion is further supported by the fact that among 5 individuals that developed the IRP phenotype during this 6-year longitudinal study, 4 were deceased at the 6-year follow-up.

Results from baseline and the 6-year follow-up also confirmed the findings from the previous OCTO Immune Study of an association between IRP and the prevalence of persistent CMV infection and demonstrated the CD8+CD28- phenotype as markedly expanded for IRP and CMV-positive individuals (Wikby et al., 2002), suggesting CMV as a contributor responsible, at least in part, for the changes producing an IRP. In line with this we found that the decline in the prevalence of IRP (from 16 to 3%) was parallel to the decline in the CMV prevalence (from 87 to 80%) between baseline and 6-year follow-up, although there were still only a small fraction of the CMV sero-positive individuals who resides in the IRP category. This aspect is also evident in the centenarians, who in spite of being CMV sero-positive did not display any T-cell changes that included increases in the number of CD8+CD28- cells associated with an IRP. These findings support the hypothesis that the manner in which CMV and the host immune system interact is critical in the development of an IRP. The expansion of apoptosis resistant virus-specific CD8+CD28- T cells related to these changes might be associated with the duration of the infection, genetic factors (Pawelec et al., 2005) and/or with the frequency of virus reactivations that might be a result of various kinds of stress (Stowe et al., 2007). Evidence for a major impact of CMV in generating CD8+CD28- cell expansions, and in the development of an IRP, was also demonstrated in the OCTO subjects by tetramer technology, showing significant increases in the frequency of CD8+ T-cells specific for a pp65 CMV peptide in IRP individuals (Ouyang et al., 2003). Recent work has also shown that the majority of T cell clonal expansions in the very old are specific for CMV, and that the attrition of this clonally expanded repertoire in IRP individuals is closely associated with survival (Reker-Hadrup et al. 2006). This suggests homeostatic T-cell changes by generation of effector CD8+ cells against CMV, with parallel

decrease in the number of CD3+CD4+ cells in order to keep the total number of CD3+ cells at a fairly constant level (Wikby et al., 2002).

Increases in the frequency of CMV-specific CD8+ cells have previously been investigated by the use of CMV peptides, representing the viral epitope from the pp65 protein (NLVPMVATV, binding HLA-A2). A frequency of 10% for this peptide in the total CD8+ repertoire in elderly people is not uncommon. It has been shown that these cells increase markedly with age and significantly in IRP individuals (Ouyang et al., 2003). Centenarians, however, seem to represent a highly selected population more “similar” to the young regarding their T-cell repertoire (Pawelec et al., 2005). A mean frequency of 1.5% of CD8+ cells specific for the NLVPMVATV epitope were reported in centenarians, which is similar to that in the young but significantly lower than that of the old at ages of 80 to 95 years (Pawelec et al., 2006). These results are in line with results from the present study, supporting the view that centenarians represent a selected elite with an absence of IRP. The results also support the view that centenarians, although “successfully aged”, are not healthy (Jeune, 2002). In the NONA Immune sample three quarters of the individuals were in fact classified as frail and at most 5% conformed to the SENIEUR criteria for being quite healthy (Wikby et al., 2006). The IRP, however, was shown to be predictive of mortality independently of the health status of the very old (Nilsson et al., 2003) and the absence of an IRP in centenarians therefore indicate a well preserved adaptive immune system, that helps to account for their survival in spite of substantial morbidity and co-morbidity.

Contrary to the finding of an absence of deleterious changes in the adaptive immune system associated with an IRP, our study demonstrate significant changes in the innate immune system as reflected in longitudinal increase in the number neutrophils, particularly in the oldest cohorts, suggesting a progression of inflammatory processes also continuing when nonagenarians become centenarians. This finding is consistent with the fact that increases in the pro-inflammatory cytokine interleukin 6, another major predictor of mortality in the very old (Wikby et al., 2006), is commonly nonetheless seen in centenarians (Pawelec et al, 2005).

The present study demonstrated that the IRP is a major predictor of mortality in octo- and nonagenarians, while the survival of centenarians is affected by a selection of nonagenarians with an immune system exhibiting no signs of a T cell Immune Risk Profile. It has also shown that the longitudinal design represents a crucial approach for allowing the detection of intra-individual change which are minimising many of the confounding artefacts likely to emerge from a cross-sectional studies in examination of relationships of age effects in a complex physiologic system like the immune system (Wikby et al., 2003).

### Acknowledgements

The authors acknowledge the considerable support of the EU project "T cell immunity and ageing", T-CIA, contract no (QLK6-CT-2001-02283), Futurum - the academy of healthcare, County Council, Jönköping and the Medical Research Council of South-east Sweden for funding of this project. We also acknowledge Länssjukhuset Ryhov for provision of laboratory resources for completion of the studies. We are indebted to our co-worker Per-Erik Evrin and would particularly like to thank the nursing staff including Lena Svensson, Lena Blom, Monica Janeblad and Gun Karlsson for their efforts in obtaining blood samples and the technical assistance of Florence Confer, Lisa Stark and Andrea Tompa.

### References

Delarosa, O., Pawelec, G., Peralbo, E., Wikby, A., Mariani, E., Mocchegiani, E., Tarazona, R., Solana, R., 2006. Immunological biomarkers of ageing in man; changes in both innate and adaptive immunity are associated with health and longevity. *Biogerontology* 7, 471-481.

Bender, B., Nagel, J., Adler, W., Andres, R., 1986. Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. *J. Amer. Geriatr. Soc.* 34, 649-654.

Effros, R.B., Boucher, N., Porter, V., Zhu, X., Spaulding, C., Kronenberg, M., Walford, R.L. Cohen, D., Schachter, F., 1994. Decline in CD8+ T-cells in centenarians and in longterm T cell cultures: a possible cause for both in vivo and in vitro senescence. *Exp. Gerontol.* 29, 601-609.

Effros, R.B., 2004. From Hayflick to Walford: the role of T cell replicative senescence in human aging. *Exp. Gerontol.* 39, 885-890.

Ferguson, F., Wikby, A., Maxson, P., Olsson, J., Johansson, B., 1995. Immune parameters in a longitudinal study of a very old population of swedish people: a comparison between survivors and nonsurvivors. *J. Gerontol. Biol. Sci.* 50A, B378-B382.

Jeune, B., 2002. Living longer – but better? *Aging Clin. Exp. Res.* 14, 72-93.

Nilsson, B.O., Ernerudh, J., Johansson, B., Evrin, P.E., Löfgren, S., Ferguson, F., Wikby, A., 2003. Morbidity does not influence the T-cell immune risk phenotype in the elderly: findings in the Swedish NONA immune study using sample selection protocols. *Mech. Ageing Dev.* 124, 469-76.

Olsson, J., Wikby, A., Johansson, B., Löfgren, S., Nilsson, B.O., Ferguson, F., 2000. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. *Mech. Ageing Develop.* 121, 187-201.

Ouyang, Q., Wagner, W., Wikby, A., Walter, S., Aubert, G., Dodi, A., Travers, P., Pawelec, G., 2003. Large number of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. *J. Clin. Immunol.* 23, 247-57.

Pawelec, G., Akbar, A., Caruso, C., Solana, R., Grubeck-Loebenstein, B., Wikby, A., 2005. Human immunosenescence: is it infectious? *Immunol. Rev.* 205, 257-68.

Pawelec, G., Koch, S., Franceschi, C., Wikby, A., 2006. Human immunosenescence: does it have an infectious component? *Ann. N Y Acad. Sci.* 1067, 56-65.

Reker-Hadrup, S., Strindhall, J., Kollgaard, T., Seremet, T., Johansson, B., Pawelec, G., thor Straten, P., Wikby, A., 2006. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and increased number of dysfunctional cytomegalovirus-specific T cells in the elderly. *J. Immunol.* 176, 2645-53.

Solana R., Pawelec G., Tarazona R. 2006. Aging and Innate Immunity. *Immunity* 24, 491-494.

Stove, R.P., Kozlova, E.V., Yetman, D.L., Walling, D.M., Goodwin, J.S., Glaser, R., 2007. Chronic herpesvirus reactivation occurs in aging. *Exp. Gerontol.* Doi:10.1016/j.exger.2007.01.005.

Wayne, S.J., Rhyne, R.L., Garry, P.J., Goodwin, J.S., 1990. Cell-mediated immunity as a predictor of morbidity and mortality in subjects over 60. *J. Gerontol.* 45, M45-M48.

Wikby, A., Maxson, P., Olsson, J., Johansson, B., Ferguson, F., 1998. Changes in CD8 and CD4 lymphocyte subsets, T-cell proliferation responses and non-survival in the very old: The Swedish longitudinal OCTO-immune study. *Mech. Ageing Develop.* 102, 187-198.

Wikby, A., Johansson, B., Olsson, J., Löfgren, S., Nilsson, B.O., Ferguson, F., 2002. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. *Exp. Gerontol.* 37, 445-53.

Wikby, A., Johansson, B., Ferguson, F., 2003. The OCTO and NONA immune longitudinal studies: a review of 11 years studies of Swedish very old humans. *Adv. Cell Aging Gerontol.* 13, 1-16.

Wikby, A., Ferguson, F., Forsey, R., Thompson, J., Strindhall, J., Löfgren, S., Nilsson, B.O., Ernerudh, J., Pawelec, G., Johansson, B., 2005. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. *J. Gerontol. A. Biol. Sci. Med. Sci.* 60, 556-65.

Wikby, A., Nilsson, B.O., Forsey, R., Thompson, J., Strindhall, J., Löfgren, S., Ernerudh, J., Pawelec, G., Ferguson, F., Johansson, B., 2006. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. *Mech Ageing Dev.* 127, 695-704.



Table 1. Characteristics of the subjects participating in the NONA Immune Longitudinal Study

| Year<br>(Time) | No. of subjects<br>investigated | Proportion of<br>women (%) | Age (years) |        |
|----------------|---------------------------------|----------------------------|-------------|--------|
|                |                                 |                            | Mean        | Range  |
| 1999 (T1)      | 138                             | 70                         | 89.8        | 86-95  |
| 2001 (T2)      | 84                              | 69                         | 91.6        | 88-97  |
| 2003 (T3)      | 55                              | 69                         | 93.2        | 90-99  |
| 2005 (T4)      | 31                              | 81                         | 94.7        | 92-101 |

Table 2. Longitudinal data for the numbers (per  $\mu\text{l}$ ) of neutrophils and lymphocytes in middle-age and very old groups of age at time 1 (T1), 2 (T2), 3 (T3) and 4 (T4)

| Parameter                                      | Time | Age at follow-up 2005 / years |                |                 |                 |
|--|------|-------------------------------|----------------|-----------------|-----------------|
|  |      | 55<br>(n=13)                  | 92<br>(n=12)   | 96<br>(n=7)     | 100<br>(n=6)    |
| Neutrophils                                    | T1   | 3686 $\pm$ 296                | 3738 $\pm$ 276 | 4094 $\pm$ 441  | 4698 $\pm$ 608  |
|  | T2   | 3646 $\pm$ 236                | 3883 $\pm$ 343 | 3914 $\pm$ 336  | 4017 $\pm$ 539  |
|  | T3   | 3031 $\pm$ 228                | 4017 $\pm$ 340 | 4114 $\pm$ 398  | 4650 $\pm$ 553  |
|  | T4   | 3338 $\pm$ 239                | 4031 $\pm$ 212 | 5110 $\pm$ 1076 | 6980 $\pm$ 2136 |
| Group p<0.05* ; Time NS ; Group by Time p<0.05 |      |                               |                |                 |                 |
| Lymphocytes                                    | T1   | 1827 $\pm$ 167                | 1865 $\pm$ 190 | 1704 $\pm$ 209  | 1768 $\pm$ 223  |
|  | T2   | 1823 $\pm$ 156                | 1717 $\pm$ 165 | 1586 $\pm$ 256  | 1817 $\pm$ 182  |
|  | T3   | 1877 $\pm$ 122                | 1800 $\pm$ 160 | 1657 $\pm$ 238  | 1717 $\pm$ 183  |
|  | T4   | 1894 $\pm$ 131                | 1859 $\pm$ 173 | 1316 $\pm$ 183  | 1487 $\pm$ 123  |
| Group NS ; Time NS ; Group by Time NS          |      |                               |                |                 |                 |

\* The MANOVA effects for group (comparison between age groups), time (time 1, 2, 3 and 4), and their interactions are shown

Table 3. Longitudinal data for the numbers (per  $\mu\text{l}$ ) of CD3+CD4+ and CD3+CD8+ and CD4/CD8 ratio in middle-age and very old groups of age at time 1 (T1), 2 (T2), 3 (T3) and 4 (T4).

| Parameter | Time                                      | Age at follow-up 2005 / years |               |               |               |
|-----------|---|-------------------------------|---------------|---------------|---------------|
|           |   | 55<br>(n=13)                  | 92<br>(n=12)  | 96<br>(n=7)   | 100<br>(n=6)  |
| CD3+CD4+  | T1  | 760 $\pm$ 84                  | 684 $\pm$ 85  | 743 $\pm$ 119 | 794 $\pm$ 108 |
|           | T2  | 783 $\pm$ 78                  | 643 $\pm$ 81  | 654 $\pm$ 125 | 833 $\pm$ 83  |
|           | T3  | 819 $\pm$ 71                  | 652 $\pm$ 78  | 692 $\pm$ 94  | 760 $\pm$ 77  |
|           | T4  | 844 $\pm$ 78                  | 663 $\pm$ 75  | 491 $\pm$ 96  | 635 $\pm$ 50  |
|           | Group NS* ; Time NS ; Group by Time NS    |                               |               |               |               |
| CD3+CD8+  | T1  | 368 $\pm$ 70                  | 452 $\pm$ 72  | 294 $\pm$ 61  | 245 $\pm$ 62  |
|           | T2  | 339 $\pm$ 52                  | 422 $\pm$ 72  | 312 $\pm$ 95  | 238 $\pm$ 67  |
|           | T3  | 395 $\pm$ 50                  | 450 $\pm$ 79  | 310 $\pm$ 76  | 226 $\pm$ 59  |
|           | T4  | 447 $\pm$ 64                  | 473 $\pm$ 61  | 221 $\pm$ 75  | 220 $\pm$ 51  |
|           | Group NS ; Time NS ; Group by Time NS     |                               |               |               |               |
| CD4/CD8   | T1  | 2.3 $\pm$ 0.2                 | 2.2 $\pm$ 0.5 | 3.0 $\pm$ 0.6 | 4.6 $\pm$ 1.2 |
|           | T2  | 2.5 $\pm$ 0.2                 | 2.3 $\pm$ 0.6 | 2.9 $\pm$ 0.5 | 5.7 $\pm$ 1.9 |
|           | T3  | 2.4 $\pm$ 0.2                 | 2.2 $\pm$ 0.5 | 3.2 $\pm$ 0.9 | 5.2 $\pm$ 1.6 |
|           | T4  | 2.1 $\pm$ 0.2                 | 1.6 $\pm$ 0.2 | 3.4 $\pm$ 1.0 | 3.8 $\pm$ 0.8 |
|           | Group p<0.05 ; Time NS ; Group by Time NS |                               |               |               |               |

\* The MANOVA effects for group (comparison between age groups), time (time 1, 2, 3 and 4), and their interactions are shown

Table 4. Longitudinal data for the numbers (per  $\mu\text{l}$ ) of CD8+CD28+ and CD8+CD28- T-cells in middle-age and very old groups of age at time 1 (T1), 2 (T2), 3 (T3) and 4 (T4)

| Parameter                                   | Time | Age at follow-up 2005 / years |              |              |              |
|---|------|-------------------------------|--------------|--------------|--------------|
|   |      | 55<br>(n=13)                  | 92<br>(n=12) | 96<br>(n=7)  | 100<br>(n=6) |
| CD8+CD28+                                   | T1   | 272 $\pm$ 36                  | 196 $\pm$ 35 | 170 $\pm$ 29 | 137 $\pm$ 26 |
|   | T2   | 272 $\pm$ 34                  | 168 $\pm$ 30 | 163 $\pm$ 37 | 134 $\pm$ 30 |
|   | T3   | 294 $\pm$ 31                  | 175 $\pm$ 29 | 146 $\pm$ 23 | 115 $\pm$ 23 |
|   | T4   | 298 $\pm$ 34                  | 180 $\pm$ 30 | 111 $\pm$ 24 | 104 $\pm$ 23 |
| Group p<0.001* ; Time NS ; Group by Time NS |      |                               |              |              |              |
| CD8+CD28-                                   | T1   | 116 $\pm$ 50                  | 274 $\pm$ 54 | 133 $\pm$ 33 | 131 $\pm$ 50 |
|   | T2   | 90 $\pm$ 32                   | 275 $\pm$ 62 | 164 $\pm$ 64 | 115 $\pm$ 40 |
|   | T3   | 142 $\pm$ 39                  | 312 $\pm$ 84 | 181 $\pm$ 67 | 142 $\pm$ 56 |
|   | T4   | 166 $\pm$ 37                  | 317 $\pm$ 60 | 121 $\pm$ 57 | 122 $\pm$ 34 |
| Group p<0.05 ; Time NS ; Group by Time NS   |      |                               |              |              |              |

\* The MANOVA effects for group (comparison between age groups), time (time 1, 2, 3 and 4), and their interactions are shown

Table 5. Student's t-tests of the numbers (per  $\mu\text{l}$ ) of neutrophils, lymphocytes and T-cells in subpopulations and CD4/CD8 ratio in survivors and non-survivors at 6-year follow-up of NONA Immune individuals



| Parameter     | Survivor<br>n=39 | Non-survivor<br>n=99 | p<    |
|---------------|------------------|----------------------|-------|
| Neutrophiles  | 4001 $\pm$ 199   | 4687 $\pm$ 161       | 0.05  |
| Lymphocytes   | 1870 $\pm$ 85    | 1850 $\pm$ 67        | NS    |
| CD3+          | 1212 $\pm$ 71    | 1178 $\pm$ 55        | NS    |
| CD3+CD4+      | 748 $\pm$ 44     | 679 $\pm$ 35         | NS    |
| CD3+CD8+      | 376 $\pm$ 35     | 448 $\pm$ 33         | NS    |
| CD8+CD28+     | 190 $\pm$ 19     | 178 $\pm$ 12         | NS    |
| CD8+CD28-     | 207 $\pm$ 26     | 299 $\pm$ 28         | 0.05  |
| CD4/CD8       | 2.9 $\pm$ 0.3    | 2.3 $\pm$ 0.2        | NS    |
| CD4/CD8<1 (%) | 0                | 22                   | 0.001 |



**Figure legends**

Figure 1. The numbers of neutrophils, lymphocytes, T-cells, and T-cell subsets for the age groups 55 (n=18), 92 (n=16), 96 (n=8) and 100 years old (n=7) at T4 follow-up. Bars represent mean values and error bars  $\pm$ SE. One-way ANOVA tests showed overall significant between group differences for the number of neutrophils ( $p<0.05$ ), CD3+ ( $p<0.01$ ), CD3+CD4+ ( $p<0.01$ ), and CD3+CD8+. Post-hoc Tukey tests indicated significant differences ( $p<0.05$ ) between the groups indicated (\*) and the 55 year old group.

Figure 2. The numbers of T-cell subsets and the CD4/CD8 ratio for the age groups 55 (n=18), 92 (n=16), 96 (n=8) and 100 years old (n=7) at the T4 follow-up. Bars represent mean values and error bars  $\pm$ SE. One-way ANOVA tests showed overall significant between group differences for the number of CD8+CD28+ ( $p<0.001$ ), CD8+CD28- ( $p<0.05$ ), and the CD4/CD8 ratio ( $p<0.01$ ). Post-hoc Tukey tests indicated significant differences ( $p<0.05$ ) between the groups indicated (\*) and the 55 year old group, the group indicated (x) and the 55 and 92 year old groups. The post-hoc test indicated a level ( $p=0.07$ ) approaching significance between the group indicated (+) and the 92 year old group.

Figure 3. The number of CD3+CD8+CD28- cells (per  $\mu$ l) plotted versus the natural logarithm of CD4/CD8 ratio by age at 6-year follow-up (2005) of NONA Immune individuals







Figure(s)

